Loading…
Reported covered position: N/A
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Issues regarding group purchasing organizations and delivery reform; H.R. 6, 21st Century Cures Act and related Senate companion bills, including innovation bills.
21st Century Cures Act
Client: BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") · Firm: ALSTON & BIRD LLP
Issues related to 21st Century Cures Act (H.R.6).
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2023 · fourth_quarter · 4T
FDA Final Rule banning tobacco flavors.
Filing targets: Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2023 · third_quarter · Q3
Source: Senate LDA
| ALLIANCE FOR QUALITY NURSING HOME CARE |
| 7 |
| 2004–2006 |
| AMERICAN ASSN FOR HOMECARE | 7 | 2004–2006 |
| CETERO RESEARCH | 7 | 2011–2012 |
| AMERICAN COLLEGE OF GASTROENTEROLOGY | 6 | 2004–2006 |
| BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. (BPCAN) | 5 | 2016 |
| MODERN HEALTH INITIATIVE | 5 | 2015 |
| AMERICAN CHIROPRACTIC ASSN | 4 | 2004–2005 |
| CVS CAREMARK INC (FORMERLY CAREMARK RX INC ) | 4 | 2004–2006 |
| FORD MOTOR CO | 4 | 2004–2005 |
| FRESENIUS MEDICAL CARE | 4 | 2004–2006 |
| HEALTH SOUTH CORPORATION | 4 | 2004–2006 |
| NORAMCO | 4 | 2019–2020 |
| ABBOTT LABORATORIES | 3 | 2004–2005 |
| ASSN FOR HEALTH INFORMATION OUTSOURCING SERVICES | 3 | 2005 |
| AVENTIS PHARMACEUTICALS | 3 | 2004 |
| BFO LIFE SCIENCES, LLC | 3 | 2015 |
| MARINE POLYMER TECHNOLOGIES | 3 | 2006–2007 |
| NDCHEALTH CORP | 3 | 2004–2005 |
| ON-E HEALTHCARE, LLC | 3 | 2010 |
| WASHINGTON2 ADVOCATES | 3 | 2004 |
| ADAMS LABORATORIES | 2 | 2004 |
| AMERIPATH | 2 | 2004 |
| CROWN LABORATORIES, INC. | 2 | 2017 |
| CSL BEHRING LLC (FORMERLY ZLB BEHRING) | 2 | 2005–2006 |
| EHEALTHINSURANCE | 2 | 2004 |
| HERITAGE PROVIDER NETWORKS | 2 | 2004 |
| JEROME STEVENS PHARMACEUTICALS | 2 | 2004 |
| ROSE ACRE FARMS, INC. | 2 | 2018 |
| US PHARMACOPEIA | 2 | 2004 |
| BRACCO DIAGNOSTICS INC. | 1 | 2007 |
| ENDO PHARMACEUTICALS | 1 | 2006 |
| KIDNEY CARE COUNCIL | 1 | 2004 |
| PARAMOUNT CAPITAL INC | 1 | 2004 |
| PHYSICIAN SALES & SERVICE INC | 1 | 2007 |
Issues regarding group purchasing organizations and delivery reform; H.R. 6, 21st Century Cures Act and related Senate companion bills, including innovation bills.
Issues regarding group purchasing organizations and delivery reform; H.R. 6, 21st Century Cures legislation & Senate Companion Bills, including innovation bills.
21st Century Cures Act
Client: BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") · Firm: ALSTON & BIRD LLP
Provisions of H.R. 6, 21st Century Cures Act and S. ____, Senate Innovations legislation related to cell therapy.
Issues regarding group purchasing organizations and delivery reform; H.R. 6, 21st Century Cures legislation & Senate Companion Bills, including innovation bills.
FDA and NIH Workforce Authorities Modernization Act
Client: BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") · Firm: ALSTON & BIRD LLP
Issues related to Senate Innovations Bill (S. 2700).
FDA and NIH Workforce Authorities Modernization Act
Client: BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") · Firm: ALSTON & BIRD LLP
Issues related to Senate Innovations Bill (S. 2700).
FDA and NIH Workforce Authorities Modernization Act
Client: BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") · Firm: ALSTON & BIRD LLP
Issues related to Senate Innovations Bill (S. 2700).
Quarterly Financial Report Reauthorization Act
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Issues related to stem cell therapy in the Senate counterpart to H.R. 6, the 21st Century Cures Act.
Issues related to stem cell therapy in the Senate counterpart to H.R. 6, the 21st Century Cures Act.
Issues related to the Senate counterpart to H.R. 6, the 21st Century Cures Act.
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Patients' Access to Treatments Act of 2013
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Fair Access for Safe and Timely Generics Act of 2014
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Protecting the Integrity of Medicare Act of 2014
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bills; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (HR 1801); Patients Access to Treatment Act of 2013 (HR 460); MODDERN Cures Act of 2013 (H.R.3116); Veterans access legislation (H.R. 3230/H.R.4810).
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Cancer Drug Coverage Parity Act of 2013
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; Issues related to coding of products; orphan drug and rare disease bill; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act of 2013 (H.R. 3116); Veterans access legislation (H.R. 3230/H.R. 4810); The America Invents Act; H.R. 5657, the FAST Generics Act of 2014.
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bills; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (HR 1801); Patients Access to Treatment Act of 2013 (HR 460); MODDERN Cures Act of 2013 (H.R.3116); Veterans access legislation (H.R. 3230/H.R.4810).
Issues relating to prescription drugs in health care bills; Issues related to coding of products; orphan drug and rare disease bill; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act of 2013 (H.R. 3116); Veterans access legislation (H.R. 3230/H.R. 4810); The America Invents Act; H.R. 5657, the FAST Generics Act of 2014.
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Patients' Access to Treatments Act of 2013
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bills; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (HR 1801); Patients Access to Treatment Act of 2013 (HR 460); MODDERN Cures Act of 2013 (H.R.3116); Veterans access legislation (H.R. 3230/H.R.4810).
Patients' Access to Treatments Act of 2013
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; Issues related to coding of products; orphan drug and rare disease bill; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act of 2013 (H.R. 3116); Veterans access legislation (H.R. 3230/H.R. 4810); The America Invents Act; H.R. 5657, the FAST Generics Act of 2014.
Patients' Access to Treatments Act of 2013
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Issues relating to prescription drugs in health care bills; Issues related to coding of products; orphan drug and rare disease bill; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act of 2013 (H.R. 3116); Veterans access legislation (H.R. 3230/H.R. 4810); The America Invents Act; H.R. 5657, the FAST Generics Act of 2014.
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bills; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (HR 1801); Patients Access to Treatment Act of 2013 (HR 460); MODDERN Cures Act of 2013 (H.R.3116); Veterans access legislation (H.R. 3230/H.R.4810).
Fair Access for Safe and Timely Generics Act of 2014
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Fair Access for Safe and Timely Generics Act of 2014
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; Issues related to coding of products; orphan drug and rare disease bill; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act of 2013 (H.R. 3116); Veterans access legislation (H.R. 3230/H.R. 4810); The America Invents Act; H.R. 5657, the FAST Generics Act of 2014.
Protecting the Integrity of Medicare Act of 2014
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Preserving Access to Orphan Drugs Act of 2011
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bills; S. 1423, Preserving Access to Orphan Drugs Act of 2011; H.R. 2672, Preserving Access to Orphan Drugs Act of 2011.
Preserving Access to Orphan Drugs Act of 2011
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bills; issues relating to pharmaceuticals in health reform, including pharmaceutical bills; S. 1423, Preserving Access to Orphan Drugs Act of 2011; H.R. 2672, Preserving Access to Orphan Drugs Act of 2011.
Medicare Fraud Enforcement and Prevention Act of 2010
Client: ON-E HEALTHCARE, LLC · Firm: ALSTON & BIRD LLP
Issues related to technology and fraud prevention; H.R. 5044/S.3632, Medicare Fraud Enforcement and Prevention Act of 2010 H.R.5546-Fighting Fraud with Innovative Technology Act; small business lending bill.
To provide for the establishment of a fraud, waste, and abuse detection and mitigation program for the Medicare Program under title XVIII of the Social Security Act.
Client: ON-E HEALTHCARE, LLC · Firm: ALSTON & BIRD LLP
Issues related to technology and fraud prevention; H.R. 5044/S.3632, Medicare Fraud Enforcement and Prevention Act of 2010 H.R.5546-Fighting Fraud with Innovative Technology Act; small business lending bill.
Physician Payment and Therapy Relief Act of 2010
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; H.R. 4213; War supplemental; H.R. 4899; H.R. 5712; the Veterans' Seniors and Children's Health Technical Corrections Act of 2010; Baucus extenders bill; drug disposal bills; orphan drug and rare disease bills; S.3697 Creating Hope Act; S.1674, Improving Access to Clinical Trials Act of 2010.
Improving Access to Clinical Trials Act of 2009
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; H.R. 4213; War supplemental; H.R. 4899; H.R. 5712; the Veterans' Seniors and Children's Health Technical Corrections Act of 2010; Baucus extenders bill; drug disposal bills; orphan drug and rare disease bills; S.3697 Creating Hope Act; S.1674, Improving Access to Clinical Trials Act of 2010.
Improving Access to Clinical Trials Act of 2009
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; the Veterans' Seniors and Children's Health Technical Corrections Act of 2010; Baucus extenders bill; drug disposal bills; orphan drug and rare disease bills; S.3697 Creating Hope Act; S. 1674, Improving Access to Clinical Trials Act of 2010.
Medicare and Medicaid Fraud Enforcement and Prevention Act of 2010
Client: ON-E HEALTHCARE, LLC · Firm: ALSTON & BIRD LLP
Issues related to technology and fraud prevention; H.R. 5044/S.3632, Medicare Fraud Enforcement and Prevention Act of 2010 H.R.5546-Fighting Fraud with Innovative Technology Act; small business lending bill.
Issues relating to prescription drugs in health care bills; H.R. 4213; War supplemental; H.R. 4899; H.R. 5712; the Veterans' Seniors and Children's Health Technical Corrections Act of 2010; Baucus extenders bill; drug disposal bills; orphan drug and rare disease bills; S.3697 Creating Hope Act; S.1674, Improving Access to Clinical Trials Act of 2010.
Issues relating to prescription drugs in health care bills; the Veterans' Seniors and Children's Health Technical Corrections Act of 2010; Baucus extenders bill; drug disposal bills; orphan drug and rare disease bills; S.3697 Creating Hope Act; S. 1674, Improving Access to Clinical Trials Act of 2010.
To amend title 5, United States Code, to increase the level of Government contributions under the Federal employees health benefits program.
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 1256, family Smoking and Prevention Act, small manufacturer provisions.
To amend title 5, United States Code, to increase the level of Government contributions under the Federal employees health benefits program.
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 1256, family Smoking and Prevention Act, small manufacturer provisions.
To amend title 5, United States Code, to increase the level of Government contributions under the Federal employees health benefits program.
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 1256, family Smoking and Prevention Act, small manufacturer provisions.
To amend the Small Business Act to provide for an increase in the amount of awards under the first and second phases of the Small Business Innovation Research program.
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; H.R. 4213; War supplemental; H.R. 4899; H.R. 5712; the Veterans' Seniors and Children's Health Technical Corrections Act of 2010; Baucus extenders bill; drug disposal bills; orphan drug and rare disease bills; S.3697 Creating Hope Act; S.1674, Improving Access to Clinical Trials Act of 2010.
Community-Based Mental Health Infrastructure Improvements Act
Client: CELGENE CORPORATION · Firm: ALSTON & BIRD LLP
Issues relating to prescription drugs in health care bills; H.R. 4213; War supplemental; H.R. 4899; H.R. 5712; the Veterans' Seniors and Children's Health Technical Corrections Act of 2010; Baucus extenders bill; drug disposal bills; orphan drug and rare disease bills; S.3697 Creating Hope Act; S.1674, Improving Access to Clinical Trials Act of 2010.
To amend title 5, United States Code, to increase the level of Government contributions under the Federal employees health benefits program.
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 1256, Family Smoking and Prevention Act, small manufacturer provisions.
To amend title 5, United States Code, to increase the level of Government contributions under the Federal employees health benefits program.
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 1256, Family Smoking and Prevention Act, small manufacturer provisions.
To amend title 5, United States Code, to increase the level of Government contributions under the Federal employees health benefits program.
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 1256, Family Smoking and Prevention Act, small manufacturer provisions.
Children's Health Insurance Program Reauthorization Act of 2007
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 3963, SCHIP Legislation, re: proposal to increase tobacco federal excise tax to fund State Children's Health Insurance Program. H.R. 1108, FDA Tobacco Legislation/Amendments, re: requirements affecting small companies imposed by Waxman FDA tobacco legislation.
Access to Capital for Haiti's Development Act
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 3963, SCHIP Legislation, re: proposal to increase tobacco federal excise tax to fund State Children's Health Insurance Program. H.R. 1108, FDA Tobacco Legislation/Amendments, re: requirements affecting small companies imposed by Waxman FDA tobacco legislation.
Terminally Ill Disability Beneficiary Act of 2003
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 976, SCHIP Legislation, provisions regarding proposal to increase federal excise tax on little cigars to fund State Children's Health Insurance Program.
Children's Health Insurance Program Reauthorization Act of 2007
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 3963, SCHIP Legislation, re: proposal to increase tobacco federal excise tax to fund State Children's Health Insurance Program. S. 625 and H.R. 1108, FDA Tobacco Legislation/Amendments, re: requirements affecting small companies imposed by Kennedy/Waxman FDA tobacco legislation.
Family Smoking Prevention and Tobacco Control Act
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 3963, SCHIP Legislation, re: proposal to increase tobacco federal excise tax to fund State Children's Health Insurance Program. S. 625 and H.R. 1108, FDA Tobacco Legislation/Amendments, re: requirements affecting small companies imposed by Kennedy/Waxman FDA tobacco legislation.
Access to Capital for Haiti's Development Act
Client: CHEYENNE INTERNATIONAL LLC · Firm: ALSTON & BIRD LLP
H.R. 3963, SCHIP Legislation, re: proposal to increase tobacco federal excise tax to fund State Children's Health Insurance Program. S. 625 and H.R. 1108, FDA Tobacco Legislation/Amendments, re: requirements affecting small companies imposed by Kennedy/Waxman FDA tobacco legislation.
FDA Final Rule banning tobacco flavors.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2023 · second_quarter · Q2
FDA final tobacco flavor ban rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2023 · first_quarter · Q1
FDA final tobacco flavor ban rule.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2023 · first_quarter · RA
FDA final tobacco flavor ban rule.
2020 · second_quarter · Q2
House and Senate Agriculture-FDA FY 2020 Appropriations legislation; FDA and USDA regulation of Cannabidiol (CBD).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2020 · second_quarter · Q2
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2020 · first_quarter · Q1
House and Senate Agriculture-FDA FY 2020 Appropriations legislation; FDA and USDA regulation of Cannabidiol (CBD).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2020 · first_quarter · Q1
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · Q4
House and Senate Agriculture-FDA FY 2020 Appropriations legislation; FDA and USDA regulation of Cannabidiol (CBD).
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2019 · fourth_quarter · Q4
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
2019 · fourth_quarter · RR
House and Senate Agriculture-FDA FY 2020 Appropriations legislation; FDA and USDA regulation of Cannabidiol (CBD).
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2019 · third_quarter · Q3
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2019 · second_quarter · Q2
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2019 · first_quarter · Q1
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2018 · fourth_quarter · 4T
Issues related to FDA review of biosimilar drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMIER, INC. via ALSTON & BIRD LLP
2018 · fourth_quarter · Q4
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2018 · fourth_quarter · Q4
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2018 · fourth_quarter · Q4
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PREMIER, INC. via ALSTON & BIRD LLP
2018 · third_quarter · Q3
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2018 · third_quarter · Q3
Issues related to FDA review of biosimilar drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2018 · third_quarter · Q3
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2018 · third_quarter · Q3
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
ROSE ACRE FARMS, INC. via ALSTON & BIRD LLP
2018 · second_quarter · 2T
Issues related to voluntary egg recall.
Issues related to voluntary egg recall.
Filing targets: Agriculture, Dept of (USDA), HOUSE OF REPRESENTATIVES, SENATE
ROSE ACRE FARMS, INC. via ALSTON & BIRD LLP
2018 · second_quarter · RR
Voluntary egg recall.
Voluntary egg recall.
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2018 · second_quarter · 2A
Issues related to FDA review of biosimilar drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMIER, INC. via ALSTON & BIRD LLP
2018 · second_quarter · Q2
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2018 · second_quarter · Q2
Issues related to FDA review of biosimilar drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2018 · second_quarter · Q2
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2018 · second_quarter · Q2
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PREMIER, INC. via ALSTON & BIRD LLP
2018 · first_quarter · Q1
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2018 · first_quarter · Q1
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2018 · first_quarter · Q1
Issues related to FDA review of biosimilar drug products.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2018 · first_quarter · Q1
Issues related to FDA regulation of tobacco products.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
PREMIER, INC. via ALSTON & BIRD LLP
2017 · fourth_quarter · Q4
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2017 · fourth_quarter · Q4
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act; Issues related to FDA biosimilar Deemed to be a License guidance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2017 · fourth_quarter · Q4
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2017 · fourth_quarter · Q4
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMIER, INC. via ALSTON & BIRD LLP
2017 · third_quarter · Q3
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2017 · third_quarter · Q3
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2017 · third_quarter · Q3
Issues regarding group purchasing organizations and health care delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2017 · third_quarter · Q3
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Consideration of increased federal excise tax for cigars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMIER, INC. via ALSTON & BIRD LLP
2017 · second_quarter · Q2
Issues regarding group purchasing organizations and delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2017 · second_quarter · Q2
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2017 · second_quarter · Q2
Issues regarding group purchasing organizations and delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Office of Management & Budget (OMB), SENATE, White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2017 · second_quarter · Q2
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PREMIER, INC. via ALSTON & BIRD LLP
2017 · first_quarter · Q1
Issues regarding group purchasing organizations and delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2017 · first_quarter · Q1
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2017 · first_quarter · Q1
Issues regarding group purchasing organizations and delivery reform.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE, White House Office
CROWN LABORATORIES, INC. via ALSTON & BIRD LLP
2017 · first_quarter · Q1
FDA Implementation of "Unapproved Drugs" Compliance Policy Guide.
Filing targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2017 · first_quarter · Q1
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CROWN LABORATORIES, INC. via ALSTON & BIRD LLP
2017 · first_quarter · RR
FDA Implementation of "Unapproved Drugs" Compliance Policy Guide.
PREMIER, INC. via ALSTON & BIRD LLP
2016 · fourth_quarter · Q4
Issues regarding group purchasing organizations and delivery reform; H.R. 6, 21st Century Cures legislation & Senate Companion Bills, including innovation bills.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE, Treasury, Dept of, White House Office
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2016 · fourth_quarter · Q4
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2016 · fourth_quarter · Q4
Issues regarding group purchasing organizations and delivery reform; H.R. 6, 21st Century Cures Act and related Senate companion bills, including innovation bills.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE, Treasury, Dept of, White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2016 · fourth_quarter · Q4
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Consideration of increased federal excise tax for cigars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") via ALSTON & BIRD LLP
2016 · fourth_quarter · 4T
Issues related to 21st Century Cures Act (H.R.6).
Filing targets: SENATE
PREMIER, INC. via ALSTON & BIRD LLP
2016 · third_quarter · Q3
Issues regarding group purchasing organizations and delivery reform; H.R. 6, 21st Century Cures legislation & Senate Companion Bills, including innovation bills.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE, Treasury, Dept of, White House Office
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2016 · third_quarter · Q3
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GREATER NEW YORK HOSPITAL ASSOCIATION via ALSTON & BIRD LLP
2016 · third_quarter · Q3
Issues regarding group purchasing organizations and delivery reform; H.R. 6, 21st Century Cures Act and related Senate companion bills, including innovation bills.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Internal Revenue Service (IRS), SENATE, Treasury, Dept of, White House Office
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2016 · third_quarter · Q3
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") via ALSTON & BIRD LLP
2016 · third_quarter · Q3
Issues related to Senate Innovations Bill (S. 2700).
Filing targets: SENATE
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2016 · second_quarter · Q2
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2016 · second_quarter · Q2
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Consideration of increased federal excise tax for cigars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") via ALSTON & BIRD LLP
2016 · second_quarter · Q2
Issues related to Senate Innovations Bill (S. 2700).
Filing targets: SENATE
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2016 · first_quarter · Q1
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2016 · first_quarter · Q1
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") via ALSTON & BIRD LLP
2016 · first_quarter · Q1
Issues related to Senate Innovations Bill (S. 2700).
Filing targets: SENATE
BIPARTISAN POLICY CENTER ADVOCACY NETWORK, INC. ("BPCAN") via ALSTON & BIRD LLP
2016 · first_quarter · RA
Provisions of H.R. 6, 21st Century Cures Act and S. ____, Senate Innovations legislation related to cell therapy.
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2015 · fourth_quarter · Q4
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODERN HEALTH INITIATIVE via ALSTON & BIRD LLP
2015 · fourth_quarter · 4T
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BFO LIFE SCIENCES, LLC via ALSTON & BIRD LLP
2015 · fourth_quarter · 4T
Issues related to stem cell therapy in the Senate counterpart to H.R. 6, the 21st Century Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SMALL BUSINESS CIGAR COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2015 · fourth_quarter · 4T
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2015 · fourth_quarter · Q4
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Consideration of increased federal excise tax for cigars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BFO LIFE SCIENCES, LLC via ALSTON & BIRD LLP
2015 · third_quarter · Q3
Issues related to stem cell therapy in the Senate counterpart to H.R. 6, the 21st Century Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
BFO LIFE SCIENCES, LLC via ALSTON & BIRD LLP
2015 · third_quarter · RR
Issues related to the Senate counterpart to H.R. 6, the 21st Century Cures Act.
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2015 · third_quarter · Q3
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODERN HEALTH INITIATIVE via ALSTON & BIRD LLP
2015 · third_quarter · Q3
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SMALL BUSINESS CIGAR COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2015 · third_quarter · Q3
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2015 · third_quarter · Q3
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODERN HEALTH INITIATIVE via ALSTON & BIRD LLP
2015 · second_quarter · 2A
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SMALL BUSINESS CIGAR COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2015 · second_quarter · Q2
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2015 · second_quarter · Q2
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2015 · second_quarter · Q2
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
MODERN HEALTH INITIATIVE via ALSTON & BIRD LLP
2015 · first_quarter · Q1
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
Filing targets: HOUSE OF REPRESENTATIVES
CELGENE CORPORATION via ALSTON & BIRD LLP
2015 · first_quarter · Q1
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
MODERN HEALTH INITIATIVE via ALSTON & BIRD LLP
2015 · first_quarter · RR
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
Issues related to pre-clinical research in the 21st Century Cures Act and the Senate counterpart to the 21st Century Cures Act.
SMALL BUSINESS CIGAR COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2015 · first_quarter · Q1
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2015 · first_quarter · Q1
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2015 · first_quarter · Q1
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2014 · fourth_quarter · 4A
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2014 · fourth_quarter · 4A
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions;FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
SMALL BUSINESS CIGAR COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2014 · fourth_quarter · Q4
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions;FDA deeming and tobacco user fee rules.
Consideration of increased federal excise tax for cigars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2014 · fourth_quarter · Q4
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2014 · fourth_quarter · Q4
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions;FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CELGENE CORPORATION via ALSTON & BIRD LLP
2014 · fourth_quarter · Q4
Issues relating to prescription drugs in health care bills; orphan drug and rare disease bill; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment of 2013 (H.R. 460); MODDERN Cures Act (H.R. 3116); H.R. 5657, the FAST Generics Act of 2014; tax extenders package; 21st Century Cures; H.R. 5780, the Protecting the Integrity of Medicare Act.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
CELGENE CORPORATION via ALSTON & BIRD LLP
2014 · third_quarter · Q3
Issues relating to prescription drugs in health care bills; Issues related to coding of products; orphan drug and rare disease bill; Family Cord Blood Banking Act; Cancer Drug Coverage Parity Act of 2013 (H.R. 1801); Patients' Access to Treatment Act of 2013 (H.R. 460); MODDERN Cures Act of 2013 (H.R. 3116); Veterans access legislation (H.R. 3230/H.R. 4810); The America Invents Act; H.R. 5657, the FAST Generics Act of 2014.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
SMALL BUSINESS CIGAR COALITION (INFORMAL COALITION) via ALSTON & BIRD LLP
2014 · third_quarter · Q3
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Consideration of increased federal excise tax for cigars.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
LANNETT COMPANY, INC. via ALSTON & BIRD LLP
2014 · third_quarter · Q3
FDA drug approval policies; Drug fee and rebate rules under the Affordable Care Act.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHEYENNE INTERNATIONAL LLC via ALSTON & BIRD LLP
2014 · third_quarter · Q3
Consideration of increased federal excise tax for cigars.
Implementation of Family Smoking Prevention and Tobacco Control Act, small manufacturer provisions; FDA deeming and tobacco user fee rules.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE